Invivyd Inc (IVVD)

$2.23 +0.29 (14.95%)
Market Cap 415.95M
Revenue (ttm) 25.38M
Net Income (ttm) -169.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -669.54%
Debt to Equity Ratio 0.00
Volume 6,791,400
Avg Vol 9,164,496
Day's Range N/A - N/A
Shares Out 214.41M
Stochastic %K 85%
Beta 0.57
Analysts Sell
Price Target $5.67

Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in pha...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 819 0080
Website: invivyd.com
Address:
1601 Trapelo Road, Suite 178, Waltham, United States
Doom_Gloom_AR
Doom_Gloom_AR Oct. 24 at 7:46 PM
$IVVD sheep of wallstreet (adar1) wanted to know if you can long this enough. I'm not sure but glad he posted it or I wouldn't of known about this.
0 · Reply
cool_io
cool_io Oct. 24 at 7:43 PM
$IVVD a lot of buying
0 · Reply
daybaron
daybaron Oct. 24 at 5:49 PM
$IVVD think i prefer the long slow slog upward than the big pop that goes right down the next day...
0 · Reply
Stopcappinbwoy
Stopcappinbwoy Oct. 24 at 5:07 PM
$IVVD beeeeeen saying this is ganna go crazy soon. and its just moving on a good market day no catalyst. it will hit $6-10 by january… HOLD
0 · Reply
cool_io
cool_io Oct. 24 at 5:05 PM
$IVVD its been a wild ride. Hopefully she has a little more in her.
0 · Reply
tkstockpicker
tkstockpicker Oct. 24 at 4:47 PM
$IVVD Jeebus Unreal, LOL
0 · Reply
none_123
none_123 Oct. 24 at 4:14 PM
Short $ICU ; Long $IVVD
0 · Reply
DARKP00L
DARKP00L Oct. 24 at 2:22 PM
$IVVD this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
cool_io
cool_io Oct. 24 at 2:02 PM
$IVVD
0 · Reply
GladysFoster
GladysFoster Oct. 23 at 10:25 AM
$IVVD is the 1.86 gunna hold????
0 · Reply
Latest News on IVVD
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 18 days ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Appoints Paul B. Bolno, M.D.

Sep 24, 2025, 4:01 PM EDT - 4 weeks ago

Invivyd Appoints Paul B. Bolno, M.D.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 17, 2025, 7:01 AM EDT - 5 weeks ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 4, 2025, 7:01 AM EDT - 7 weeks ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Aug 29, 2025, 9:55 AM EDT - 2 months ago

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Invivyd to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:01 AM EDT - 2 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 22, 2025, 12:00 PM EDT - 2 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 11:58 PM EDT - 2 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

Aug 20, 2025, 4:01 PM EDT - 2 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 18, 2025, 4:32 PM EDT - 2 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:49 PM EDT - 2 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 4:47 PM EDT - 2 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 23, 2025, 7:01 AM EDT - 3 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 21, 2025, 7:05 AM EDT - 3 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 2, 2025, 7:01 AM EDT - 4 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Jun 26, 2025, 7:01 AM EDT - 4 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025, 7:01 AM EDT - 5 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025, 7:01 AM EDT - 5 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025, 9:30 AM EDT - 5 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

May 15, 2025, 11:08 AM EDT - 5 months ago

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 7:01 AM EDT - 5 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 14, 2025, 7:01 AM EDT - 5 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 7:01 AM EDT - 5 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 12, 2025, 7:01 AM EDT - 5 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:01 AM EDT - 6 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Apr 21, 2025, 7:01 AM EDT - 6 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 26, 2025, 4:15 PM EDT - 7 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 20, 2025, 8:01 AM EDT - 7 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Mar 5, 2025, 7:05 AM EST - 8 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 9:20 AM EST - 8 months ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 8 months ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Feb 10, 2025, 7:00 AM EST - 9 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Feb 5, 2025, 9:30 AM EST - 9 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 4, 2025, 3:55 PM EST - 9 months ago

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Feb 3, 2025, 6:55 AM EST - 9 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Jan 27, 2025, 7:01 AM EST - 9 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Jan 10, 2025, 7:01 AM EST - 10 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:15 PM EST - 1 year ago

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:05 AM EST - 1 year ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Nov 14, 2024, 7:01 AM EST - 1 year ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Nov 12, 2024, 8:30 AM EST - 1 year ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 8:01 AM EST - 1 year ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Nov 6, 2024, 7:01 AM EST - 1 year ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Oct 29, 2024, 7:03 AM EDT - 1 year ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Oct 29, 2024, 7:01 AM EDT - 1 year ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Oct 16, 2024, 7:01 AM EDT - 1 year ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Oct 1, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Sep 23, 2024, 7:01 AM EDT - 1 year ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Sep 12, 2024, 7:01 AM EDT - 1 year ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Sep 4, 2024, 7:01 AM EDT - 1 year ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Doom_Gloom_AR
Doom_Gloom_AR Oct. 24 at 7:46 PM
$IVVD sheep of wallstreet (adar1) wanted to know if you can long this enough. I'm not sure but glad he posted it or I wouldn't of known about this.
0 · Reply
cool_io
cool_io Oct. 24 at 7:43 PM
$IVVD a lot of buying
0 · Reply
daybaron
daybaron Oct. 24 at 5:49 PM
$IVVD think i prefer the long slow slog upward than the big pop that goes right down the next day...
0 · Reply
Stopcappinbwoy
Stopcappinbwoy Oct. 24 at 5:07 PM
$IVVD beeeeeen saying this is ganna go crazy soon. and its just moving on a good market day no catalyst. it will hit $6-10 by january… HOLD
0 · Reply
cool_io
cool_io Oct. 24 at 5:05 PM
$IVVD its been a wild ride. Hopefully she has a little more in her.
0 · Reply
tkstockpicker
tkstockpicker Oct. 24 at 4:47 PM
$IVVD Jeebus Unreal, LOL
0 · Reply
none_123
none_123 Oct. 24 at 4:14 PM
Short $ICU ; Long $IVVD
0 · Reply
DARKP00L
DARKP00L Oct. 24 at 2:22 PM
$IVVD this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
cool_io
cool_io Oct. 24 at 2:02 PM
$IVVD
0 · Reply
GladysFoster
GladysFoster Oct. 23 at 10:25 AM
$IVVD is the 1.86 gunna hold????
0 · Reply
billsmall
billsmall Oct. 23 at 12:32 AM
$IVVD anyone think they're using the ATM down here?
0 · Reply
tkstockpicker
tkstockpicker Oct. 22 at 3:20 PM
$IVVD stopped on rest of trading shares for 170% gain. Core still not touched.
0 · Reply
Gj64
Gj64 Oct. 22 at 2:33 PM
$IVVD GRTX https://www.stocktitan.net/news/GRTX/galera-therapeutics-announces-acquisition-of-dismutase-mimetics-8pulrnbo7s22.html
0 · Reply
Rynr
Rynr Oct. 22 at 1:48 PM
$IVVD
0 · Reply
trader2sde
trader2sde Oct. 22 at 2:49 AM
$IVVD some big guys who got the dollar entry may have arranged an exit with a double. the big gains will be next year. market is dangerous these days for many reasons.
1 · Reply
Swamp_Yankee
Swamp_Yankee Oct. 21 at 10:17 PM
$IVVD this looks strong for another run tomorrow. Maybe past 2.30. We will see.
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 21 at 7:32 PM
$IVVD has reverted -3% lower to 3% (~8Mv) a moment ago, 11/21 options, follow for more volatility.
0 · Reply
Sw1ngb0t
Sw1ngb0t Oct. 21 at 4:14 PM
$IVVD got it
0 · Reply
alexx013
alexx013 Oct. 21 at 3:38 PM
$IVVD out for now, I sold remaining 20% @ 2.19
0 · Reply
VANGOO
VANGOO Oct. 21 at 3:22 PM
$IVVD Next FIB target.... #3.22
0 · Reply
alexx013
alexx013 Oct. 21 at 3:19 PM
$IVVD sold all but 20% @ 2.23
1 · Reply
none_123
none_123 Oct. 21 at 2:57 PM
Short $ICU, LONG $IVVD
0 · Reply